Form 4: Entrada Therapeutics President & COO Nathan Dowden Reports Stock Sales

Nathan Dowden, President & COO of Entrada Therapeutics, sold shares of common stock on September 6 and September 9, 2024, according to a Form 4 filing.

Summary

• On September 6, 2024, Nathan Dowden, the President & COO of Entrada Therapeutics, sold 399 shares of common stock at a weighted average price of $15.1947.
• On September 9, 2024, Dowden sold 1,904 shares of common stock at a weighted average price of $15.0684.
• Following these transactions, Dowden directly owns 125,996 shares of Entrada Therapeutics.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 8, 2024.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock sales by a company executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider transactions.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders buy or sell their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's valuation and future prospects.

Stakeholder Impact

• Shareholders may interpret the stock sales as a lack of confidence by the executive, although the sales were conducted under a pre-arranged trading plan.

Key Dates